×
About 1,501,044 results
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://doi.org/10.1056/NEJMoa1805762
The New England Journal of Medicine; Dimopoulos MA, Dytfeld D et. al.

Nov 7th, 2018 - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Patients with multiple myeloma t...

Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188122
MMWR. Morbidity and Mortality Weekly Report; Kahn KE, Black CL et. al.

Sep 27th, 2018 - Vaccinating pregnant women with influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines can reduce the risk for influenza and pertussis for themselves and their infants. The Advisory Committee on Immunization Practices (ACIP) recommends that all women who are or might be pregnant during the influenza season receive influenza vaccine, which can be adminis...

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
https://doi.org/10.1056/NEJMoa1800149
The New England Journal of Medicine; Chitnis T, Arnold DL et. al.

Sep 12th, 2018 - Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for ...

A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
https://doi.org/10.1056/NEJMoa1803760
The New England Journal of Medicine; Fenske W, Refardt J et. al.

Aug 1st, 2018 - The indirect water-deprivation test is the current reference standard for the diagnosis of diabetes insipidus. However, it is technically cumbersome to administer, and the results are often inaccurate. The current study compared the indirect water-deprivation test with direct detection of plasma copeptin, a precursor-derived surrogate of arginine vasopressin. From 2013 to 2017, we recruited 156...

Safety and Side Effects of Rifampin versus Isoniazid in Children.
https://doi.org/10.1056/NEJMoa1714284
The New England Journal of Medicine; Diallo T, Adjobimey M et. al.

Aug 1st, 2018 - The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been s...

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
https://doi.org/10.1053/j.gastro.2017.12.012
Gastroenterology Hadjiliadis D, Khoruts A et. al.

Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...

Five-year results of brentuximab vedotin in patients with relapsed or refractory system...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746164
Blood Pro B, Advani R et. al.

Oct 4th, 2017 - This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated o...

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.
https://doi.org/10.1056/NEJMoa1703309
The New England Journal of Medicine; Cardemil CV, Dahl RM et. al.

Sep 6th, 2017 - The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown. During an outbreak among vaccinated students at the University of Iowa, health officials implemented a widespread MMR vaccine campaign. We evaluated the effectiveness of a third dose for outbreak control and assessed for waning immunity. Of 20,496 university students who were enrolled ...

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620419
Blood Jabbour E, Short NJ et. al.

Aug 4th, 2017 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, a...

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Clas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Chen R, Zinzani PL et. al.

Apr 25th, 2017 - Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifie...

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965
The New England Journal of Medicine; Hochhaus A, Larson RA et. al.

Mar 8th, 2017 - Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed C...

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Gro...
https://doi.org/10.1200/JCO.2016.71.3289
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bröckelmann PJ, Goergen H et. al.

Feb 27th, 2017 - Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. P...

Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529262
Arthritis Care & Research; George MD, Baker JF et. al.

Jan 27th, 2017 - The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who re...

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
https://doi.org/10.1056/NEJMoa1513257
The New England Journal of Medicine; Roberts AW, Davids MS et. al.

Dec 7th, 2015 - New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma...

FDA approves first therapy to treat patients with rare blood disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder
FDA FDA

Nov 9th, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
https://ascopost.com/issues/november-10-2019/prima-trial-reports-benefit-with-niraparib-across-ovarian-cancer-subsets/
ASCO Post; Helwick C

Nov 9th, 2019 - In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the PARP inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a homologous recombination deficiency derived advantage from this treatment, in the phase III PRIMA/ENGOT-OV26/GOG-3012 trial presente...

Men With BRCA2 Should Be Screened for Prostate Cancer
https://www.medscape.com/viewarticle/921000
Medscape Davenport L

Nov 7th, 2019 - Men who carry the BRCA2 gene mutation, which is linked to breast and ovarian cancer, are at risk of developing aggressive prostate cancer and so should undergo regular prostate-specific antigen (PSA) testing, suggest findings from a major study.

Diffuse Large B-Cell Lymphoma
https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/
Lymphoma Research Foundation;

Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
https://www.nejm.org/doi/full/10.1056/NEJMoa1909953
The New England Journal of Medicine; Tait, D. et. al.

Oct 28th, 2019 - BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS From August 201...